Why Cooperation is a Better Strategy to Achieve Competitive Advantage in Immuno-Oncology for Pharma Rivals Pfizer and Merck KGaA - Analyzing the Companies' Benefits

Abstract

Biotech revolution changed the pharmaceutical industry, triggering a wave of risky collaborations between rivals. Based on the research findings, we answer the question why cooperation in the field of immuno-oncology is a better strategy for Pfizer and Merck KGaA, which aim to achieve competitive advantage quickly and with minimum effort. Combining their assets and core expertise companies realize benefits of greater size and variety in the conduct of research, development and commercializing of their new breakthrough therapy for cancer treatment.